| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2023 | Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
| JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
| 2023 | A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
| CANCER RESEARCH AND TREATMENT |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
| DIAGNOSTICS |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
| ESMO OPEN |
| 2023 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| CANCER RESEARCH AND TREATMENT |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2023 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2023 | Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
| CANCER SCIENCE |
| 2023 | Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
| CANCER RESEARCH AND TREATMENT |
| 2023 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2022 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
| JAMA ONCOLOGY |
| 2022 | Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2022 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
| CANCERS |
| 2022 | Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant | CLINICAL CANCER RESEARCH |
| 2022 | Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
| ANNALS OF ONCOLOGY |
| 2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
| ANNALS OF ONCOLOGY |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2021 | Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) | ESMO OPEN |
| 2021 | Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
| PHARMACEUTICALS |
| 2021 | Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
| CANCER RESEARCH AND TREATMENT |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial | LANCET ONCOLOGY |
| 2021 | Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
| BRITISH JOURNAL OF CANCER |
| 2021 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
| 2021 | Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
| JCO PRECISION ONCOLOGY |
| 2021 | Regarding the article by Rugo Reply
| ONCOLOGIST |
| 2021 | Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective | ANNALS OF SURGERY |
| 2021 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials | CANCER SCIENCE |
| 2021 | Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
| NPJ BREAST CANCER |
| 2021 | Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy
| SCIENTIFIC REPORTS |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs | Clinical and Translational Science |
| 2021 | A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
| ANNALS OF ONCOLOGY |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | EUROPEAN JOURNAL OF CANCER |
| 2021 | Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
| ONCOLOGIST |
| 2021 | A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2020 | Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib | BREAST CANCER RESEARCH AND TREATMENT |
http://orcid.org/0000-0002-2303-2764
(15045889800)
